NASDAQ: UPXIUpexi Inc Stock
$1.17+0.01 (+0.86%)
Updated Oct 2, 2026
UPXI Price
$1.17
Fair Value Price
N/A
Market Cap
$96.06M
52 Week Low
$0.54
52 Week High
$7.75
P/E
-0.3x
P/B
-1.79x
P/S
1.99x
PEG
N/A
Dividend Yield
N/A
Revenue
$25.00M
Earnings
-$246.06M
Gross Margin
89.5%
Operating Margin
-930.09%
Profit Margin
-984.3%
Debt to Equity
-4.35
Operating Cash Flow
-$21M
Beta
0.63
Next Earnings
Nov 10, 2026
Ex-Dividend
N/A
Next Dividend
N/A
UPXI Overview
Upexi, Inc. engages in the development, manufacture, and distribution of consumer products. It offers nail grinder and healthy all-natural pet supplements under the LuckyTail brand; energy solutions under the PRAX brand; functional mushrooms under the Cure Mushrooms brand; cannabinoid under the Moonwlkr brand; and gummies and other products under the Gumi Labs brand name. The company sells its products through direct-to-consumer network, wholesale partnerships, and third-party platform. It also focuses on cryptocurrency industry and management of cash assets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. Upexi, Inc. was incorporated in 2018 and is headquartered in Tampa, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine UPXI's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Internet Content & Information
Industry Rating
D
UPXI
Ranked#43 of 49
Ranked#43 of 49
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.62 | A | |
| $3.00 | A | |
| $16.64 | B |
Be the first to know about important UPXI news, forecast changes, insider trades & much more!
UPXI News
Overview
Due Diligence Score
–
Industry Average (31)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how UPXI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
UPXI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
UPXI is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
UPXI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more UPXI due diligence checks available for Premium users.
Valuation
UPXI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.3x
Industry
45.53x
Market
49.66x
UPXI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.79x
Industry
6.26x
UPXI's financial health
Profit margin
Revenue
$3.1M
Net Income
-$24.5M
Profit Margin
-779.4%
UPXI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
UPXI's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$180.1M
Liabilities
$233.9M
Debt to equity
-4.35
UPXI's short-term assets ($116.77M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
UPXI's long-term liabilities ($162.80M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
UPXI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
UPXI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.7M
Investing
-$1.7M
Financing
$7.7M
UPXI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
UPXI vs Internet Content & Information Stocks
Upexi Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.